We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+6.85%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$189M
AUM Growth
+$25.9M
Cap. Flow
+$19M
Cap. Flow %
10.03%
Top 10 Hldgs %
53.85%
Holding
93
New
27
Increased
23
Reduced
15
Closed
5

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$2.5M
2
TPB icon
Turning Point Brands
TPB
+$1.88M
3
AMGN icon
Amgen
AMGN
+$1.6M
4
JNJ icon
Johnson & Johnson
JNJ
+$987K
5
IWM icon
iShares Russell 2000 ETF
IWM
+$588K

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$3.59M
2
BIIB icon
Biogen
BIIB
+$1.36M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$1.08M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$713K
5
NEM icon
Newmont
NEM
+$368K

Sector Composition

Rank Sector Weight
1 Healthcare 35.09%
2 Technology 14.46%
3 Communication Services 6.26%
4 Consumer Discretionary 3.14%
5 Energy 2.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$35.7M 18.85%
80,500
+19,000
+31% +$7.97M
MU icon
2
Micron Technology
MU
$930B
$10.1M 5.32%
159,500
+2,000
+1% +$129K
ARGX icon
3
argenx
ARGX
$53.4B
$10M 5.29%
25,700
– –
GOOG icon
4
Alphabet (Google) Class C
GOOG
$4.36T
$8.67M 4.58%
71,650
-9,350
-12% -$1.08M
REGN icon
5
Regeneron Pharmaceuticals
REGN
$78.5B
$8.03M 4.24%
11,175
+150
+1% +$116K
ITCI
6
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.79M 3.58%
107,157
-11,443
-10% -$713K
ABBV icon
7
AbbVie
ABBV
$443B
$6.41M 3.38%
47,550
-24,450
-34% -$3.59M
PRTA icon
8
Prothena Corp
PRTA
$425M
$5.79M 3.06%
84,750
+500
+0.6% +$32.3K
XNCR icon
9
Xencor
XNCR
$1.5B
$5.37M 2.84%
215,000
+5,000
+2% +$136K
ORCL icon
10
Oracle
ORCL
$374B
$5.12M 2.71%
43,000
– –
ET icon
11
Energy Transfer Partners
ET
$70.1B
$4.79M 2.53%
377,000
+3,000
+0.8% +$38K
BAC icon
12
Bank of America
BAC
$435B
$3.94M 2.08%
137,250
-750
-0.5% -$21.4K
GLD icon
13
SPDR Gold Trust
GLD
$131B
$3.83M 2.02%
21,500
– –
AMGN icon
14
Amgen
AMGN
$208B
$3.75M 1.98%
16,875
+6,875
+69% +$1.6M
IAU icon
15
iShares Gold Trust
IAU
$62.9B
$3.64M 1.92%
100,000
– –
LLY icon
16
Eli Lilly
LLY
$1.02T
$3.52M 1.86%
7,500
-750
-9% -$315K
AMD icon
17
Advanced Micro Devices
AMD
$776B
$3.47M 1.84%
30,500
+500
+2% +$52K
AAPL icon
18
Apple
AAPL
$4.54T
$2.86M 1.51%
14,750
– –
ZBH icon
19
Zimmer Biomet
ZBH
$18.2B
$2.68M 1.42%
+18,397
New +$2.5M
GLD icon
20
PUT
SPDR Gold Trust
GLD
$131B
$2.58M 1.37%
+14,500
New +$2.66M
INCY icon
21
Incyte
INCY
$24.2B
$2.52M 1.33%
40,500
-2,000
-5% -$134K
SGEN
22
DELISTED
Seagen Inc. Common Stock
SGEN
$2.24M 1.18%
11,650
-500
-4% -$99.3K
AOD
23
abrdn Total Dynamic Dividend Fund
AOD
$1.11B
$2.09M 1.11%
253,500
– –
T icon
24
AT&T
T
$159B
$2.03M 1.07%
127,500
– –
TPB icon
25
Turning Point Brands
TPB
$1.45B
$2M 1.06%
+83,500
New +$1.88M
1
2 3 4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q2 2023 Portfolio in Review

As of Q2 2023, DCF Advisers held 93 positions worth $189M, up 16% from $163M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

DCF Advisers deployed $19M of net new capital in Q2 2023, opening 27 new positions and adding to 23 existing holdings. Its largest new stake was Zimmer Biomet: 18,397 shares worth $2.68M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 40% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was AbbVie, an estimated $3.59M trimmed.

  • DCF Advisers's largest Q2 2023 buy was Zimmer Biomet: 18,397 shares worth $2.68M.
  • DCF Advisers added most to Amgen in Q2 2023, an estimated $1.6M increase.
  • DCF Advisers's biggest Q2 2023 reduction was AbbVie, cutting an estimated $3.59M.
  • DCF Advisers fully exited Biogen in Q2 2023, selling an estimated $1.36M.
  • DCF Advisers's ten largest holdings make up 54% of its $189M portfolio in Q2 2023.
  • DCF Advisers opened 27 new positions and closed 5 in Q2 2023.
  • DCF Advisers's portfolio value rose 16% quarter-over-quarter to $189M.

Based on DCF Advisers's 13F filing for Q2 2023, filed 9 Aug 2023.